MPPED2

Summary

MPPED2 (metallophosphoesterase domain containing 2, HGNC:1180) is a protein-coding gene on chromosome 11p14.1, encoding Metallophosphoesterase MPPED2 (Q15777). Displays low metallophosphoesterase activity (in vitro).

Predicted to enable manganese ion binding activity; phosphoric diester hydrolase activity; and purine ribonucleotide binding activity.

Source: NCBI Gene 744 — RefSeq curated summary.

At a glance

• GWAS associations: 40
• Clinical variants (ClinVar): 25 total
• MANE Select transcript: NM_001584

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1180
Approved symbol	MPPED2
Name	metallophosphoesterase domain containing 2
Location	11p14.1
Locus type	gene with protein product
Status	Approved
Aliases	239FB, D11S302E, Hs.46638, FAM1B, dJ873F21.1, dJ1024C24.1
Ensembl gene	ENSG00000066382
Ensembl biotype	protein_coding
OMIM	600911
Entrez	744

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 10 protein_coding, 3 protein_coding_CDS_not_defined, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000358117, ENST00000448418, ENST00000524636, ENST00000524667, ENST00000525519, ENST00000526437, ENST00000528686, ENST00000529220, ENST00000904183, ENST00000904184, ENST00000904185, ENST00000904186, ENST00000904187, ENST00000943646, ENST00000943647

RefSeq mRNA: 7 — MANE Select: NM_001584 NM_001145399, NM_001377952, NM_001377953, NM_001377954, NM_001377955, NM_001377956, NM_001584

CCDS: CCDS44560, CCDS7870

Canonical transcript exons

ENST00000358117 — 7 exons

Exon	Start	End
ENSE00000708211	30535994	30536175
ENSE00001421770	30410224	30411586
ENSE00001763348	30580246	30580494
ENSE00003507488	30417518	30417633
ENSE00003522524	30414228	30414341
ENSE00003617436	30495296	30495521
ENSE00003911771	30586042	30586353

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 99.09.

FANTOM5 (CAGE): breadth broad, TPM avg 4.1439 / max 159.0528, expressed in 668 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
119115	2.3939	610
119113	0.6204	339
119116	0.3665	167
119117	0.2459	99
119114	0.1941	120
119118	0.1143	53
119112	0.0980	34
119111	0.0663	18
119119	0.0445	22

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	99.09	gold quality
ganglionic eminence	UBERON:0004023	98.78	gold quality
cortical plate	UBERON:0005343	96.48	gold quality
buccal mucosa cell	CL:0002336	93.86	gold quality
thyroid gland	UBERON:0002046	92.95	gold quality
left lobe of thyroid gland	UBERON:0001120	92.56	gold quality
right lobe of thyroid gland	UBERON:0001119	92.20	gold quality
parotid gland	UBERON:0001831	92.10	gold quality
right uterine tube	UBERON:0001302	91.82	gold quality
tibia	UBERON:0000979	88.15	gold quality
adrenal tissue	UBERON:0018303	87.65	gold quality
nucleus accumbens	UBERON:0001882	87.12	gold quality
prostate gland	UBERON:0002367	86.39	gold quality
pigmented layer of retina	UBERON:0001782	86.29	gold quality
embryo	UBERON:0000922	85.82	gold quality
pons	UBERON:0000988	85.38	gold quality
endothelial cell	CL:0000115	85.31	gold quality
pituitary gland	UBERON:0000007	85.16	gold quality
caudate nucleus	UBERON:0001873	85.05	gold quality
putamen	UBERON:0001874	85.03	gold quality
descending thoracic aorta	UBERON:0002345	84.44	gold quality
prefrontal cortex	UBERON:0000451	84.41	gold quality
seminal vesicle	UBERON:0000998	84.32	gold quality
adenohypophysis	UBERON:0002196	84.07	gold quality
renal medulla	UBERON:0000362	84.04	gold quality
ascending aorta	UBERON:0001496	83.94	gold quality
thoracic aorta	UBERON:0001515	83.93	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	81.99	gold quality
Brodmann (1909) area 9	UBERON:0013540	81.42	gold quality
telencephalon	UBERON:0001893	81.05	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	44.45
E-HCAD-5	yes	22.34
E-MTAB-7316	yes	21.00
E-ANND-3	yes	6.31
E-GEOD-100618	no	182.73

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F1, ESR1, EWSR1, NR3C2, PAX5, TP53, ZBTB7B

miRNA regulators (miRDB)

92 targeting MPPED2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-10523-5P	99.91	69.22	2038

Literature-anchored findings (GeneRIF, showing 6)

• The structures of MPPED2 and two mutants show that the poor activity of MPPED2 is not only a consequence of the substitution of an active-site histidine residue by glycine but also due to binding of AMP or GMP to the active site. (PMID:21824479)
• The overexpression of Mpped2 improves survival rate, substantially impairs tumor growth and induces neuronal differentiation. (PMID:22262177)
• Findings indicate that epigenetic alterations of MPPED2 promoter region appear sequentially during the colorectal neoplastic progression. (PMID:30846004)
• CTN2 (rs6655267) and MPPED2 (rs536007) are not associated with primary dentition caries. MPPED2 (rs11031093, G Allele) is marginally associated. (PMID:32040219)
• MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells. (PMID:33734003)
• Association of MPPED2 gene variant rs10767873 with kidney function and risk of cardiovascular disease in patients with hypertension. (PMID:36797372)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	mpped2a	ENSDARG00000006889
danio_rerio	mpped2	ENSDARG00000034443
mus_musculus	Mpped2	ENSMUSG00000016386
rattus_norvegicus	Mpped2	ENSRNOG00000004863
drosophila_melanogaster	CG16717	FBGN0036028
caenorhabditis_elegans		WBGENE00011579
caenorhabditis_elegans		WBGENE00016101
caenorhabditis_elegans		WBGENE00019479

Paralogs (1): MPPED1 (ENSG00000186732)

Protein

Protein identifiers

Metallophosphoesterase MPPED2 — Q15777 (reviewed: Q15777)

Alternative names: Fetal brain protein 239, Metallophosphoesterase domain-containing protein 2

All UniProt accessions (3): Q15777, E9PQW8, F2Z346

UniProt curated annotations — full annotation on UniProt →

Function. Displays low metallophosphoesterase activity (in vitro). May play a role in the development of the nervous system.

Subunit / interactions. Homodimer.

Tissue specificity. Expressed predominantly in fetal brain.

Activity regulation. Inhibited by nmolar levels of AMP and GMP.

Similarity. Belongs to the UPF0046 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q15777-1	1	yes
Q15777-2	2

RefSeq proteins (7): NP_001138871, NP_001364881, NP_001364882, NP_001364883, NP_001364884, NP_001364885, NP_001575* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004843	Calcineurin-like_PHP	Domain
IPR024201	Calcineurin-like_Pesterase	Family
IPR029052	Metallo-depent_PP-like	Homologous_superfamily
IPR051693	UPF0046_metallophosphoest	Family

Pfam: PF00149

UniProt features (13 total): binding site 10, chain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15777-F1	95.43	0.92

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (10): 65; 254; 67; 86; 86; 117–118; 117; 213; 225–226; 252–255

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 208 (showing top): SHEPARD_BMYB_MORPHOLINO_UP, LEE_NEURAL_CREST_STEM_CELL_DN, YAATNRNNNYNATT_UNKNOWN, GCANCTGNY_MYOD_Q6, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOZGIT_ESR1_TARGETS_DN, TGACCTY_ERR1_Q2, AAAYRNCTG_UNKNOWN, CAGCTG_AP4_Q5, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN, AGTCTTA_MIR499, CEBP_Q2, MORF_ZNF10, SETLUR_PROSTATE_CANCER_TMPRSS2_ERG_FUSION_DN

GO Biological Process (0):

GO Molecular Function (8): phosphoric diester hydrolase activity (GO:0008081), AMP binding (GO:0016208), GMP binding (GO:0019002), manganese ion binding (GO:0030145), nucleotide binding (GO:0000166), protein binding (GO:0005515), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
anion binding	2
cation binding	2
phosphoric ester hydrolase activity	1
adenyl ribonucleotide binding	1
guanyl ribonucleotide binding	1
transition metal ion binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1

Protein interactions and networks

STRING

680 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MPPED2	DCDC1	P59894	905
MPPED2	DNAJC24	Q6P3W2	888
MPPED2	IMMP1L	Q96LU5	872
MPPED2	ELP4	Q96EB1	855
MPPED2	FSHB	P01225	707
MPPED2	PAX6	P26367	699
MPPED2	KRT12	Q99456	497
MPPED2	D6RI10	D6RI10	454
MPPED2	TBC1D30	Q9Y2I9	429
MPPED2	EDARADD	Q8WWZ3	417
MPPED2	ARL14EP	Q8N8R7	397
MPPED2	WT1	P19544	372
MPPED2	CCDC187	A0A096LP49	371
MPPED2	AJAP1	Q9UKB5	370
MPPED2	GPR149	Q86SP6	367

IntAct

55 interactions, top by confidence:

A	B	Type	Score
MPPED2	TRIP13	psi-mi:“MI:0915”(physical association)	0.790
TRIP13	MPPED2	psi-mi:“MI:0915”(physical association)	0.790
NCKAP1	YWHAH	psi-mi:“MI:0914”(association)	0.730
RXRG	MPPED2	psi-mi:“MI:0915”(physical association)	0.720
VAC14	MPPED2	psi-mi:“MI:0915”(physical association)	0.720
MPPED2	RXRG	psi-mi:“MI:0915”(physical association)	0.720
FAM72A	MPPED2	psi-mi:“MI:0915”(physical association)	0.560
MPPED2	CAGE1	psi-mi:“MI:0915”(physical association)	0.560
CAGE1	MPPED2	psi-mi:“MI:0915”(physical association)	0.560
MPPED2	FAM72A	psi-mi:“MI:0915”(physical association)	0.560
MPPED2	HOOK2	psi-mi:“MI:0915”(physical association)	0.560
MPPED2	NUP93	psi-mi:“MI:0915”(physical association)	0.560
MPPED2	RIBC1	psi-mi:“MI:0915”(physical association)	0.560
MPPED2	POMP	psi-mi:“MI:0915”(physical association)	0.560
MPPED2	MBD3L1	psi-mi:“MI:0915”(physical association)	0.560
MPPED2	BEX4	psi-mi:“MI:0915”(physical association)	0.560
MPPED2	NR2F6	psi-mi:“MI:0914”(association)	0.530
MPPED2	IKZF1	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (31): RXRG (Two-hybrid), TRIP13 (Two-hybrid), VAC14 (Two-hybrid), CAGE1 (Two-hybrid), FAM72A (Two-hybrid), MPPED2 (Reconstituted Complex), NR2F6 (Affinity Capture-MS), MPPED2 (Affinity Capture-MS), MPPED2 (Two-hybrid), TRIP13 (Two-hybrid), NR2F6 (Affinity Capture-MS), SULT1A3 (Affinity Capture-MS), TRIP13 (Two-hybrid), HOOK2 (Two-hybrid), BEX4 (Two-hybrid)

ESM2 similar proteins: A0A067XMV3, A0A179HLJ8, A0A1L9WLF1, A0A2I1C3U0, A0A411PQM3, A0A4P8DJU1, A0A4V1E8I5, A0A5B8YUX5, A0A7R7ZLL0, A1D8J2, A2QX23, B1WBP0, C3K630, C5FM60, D4CZZ5, D7PHZ3, D7PHZ8, E1ACR1, E4V2N5, F2PWS8, F2S702, F2T0M3, G3KLH5, K3VFR8, M1WCF7, M3ANL0, P0CM88, P0CM89, P0CU68, P25170, P9WEG2, Q0CCY4, Q0CJ62, Q0CS61, Q0CS91, Q15777, Q26547, Q4W945, Q4WA58, Q4WAZ0

Diamond homologs: B1WBP0, O15442, Q15777, Q18161, Q21268, Q22306, Q5B5P1, Q5REB1, Q91ZG2, Q9CZJ0, A1D144, A5ABH4, B0XPA2, B8N5T6, Q0C7K7, Q2U5P7, Q2UDJ8, Q4WR79, Q5AZ85

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

25 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	14
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2180 predictions. Top by Δscore:

Variant	Effect	Δscore
11:30414222:TCTTA:T	donor_loss	1.0000
11:30414223:CTTA:C	donor_loss	1.0000
11:30414224:TTACC:T	donor_loss	1.0000
11:30414225:TAC:T	donor_loss	1.0000
11:30414226:A:C	donor_loss	1.0000
11:30414227:C:A	donor_loss	1.0000
11:30423991:T:TA	donor_gain	1.0000
11:30495294:A:AC	donor_gain	1.0000
11:30495295:C:CC	donor_gain	1.0000
11:30495295:CCAAG:C	donor_gain	1.0000
11:30495517:GTTTC:G	acceptor_gain	1.0000
11:30495518:TTTC:T	acceptor_gain	1.0000
11:30495519:TTC:T	acceptor_gain	1.0000
11:30495520:TC:T	acceptor_gain	1.0000
11:30495520:TCC:T	acceptor_loss	1.0000
11:30495521:CC:C	acceptor_gain	1.0000
11:30495522:C:CC	acceptor_gain	1.0000
11:30580244:A:AC	donor_gain	1.0000
11:30580245:C:CA	donor_gain	1.0000
11:30580245:CA:C	donor_gain	1.0000
11:30580245:CAT:C	donor_gain	1.0000
11:30580245:CATA:C	donor_gain	1.0000
11:30411438:C:A	donor_gain	0.9900
11:30414341:CCTA:C	acceptor_loss	0.9900
11:30414343:T:G	acceptor_loss	0.9900
11:30423992:C:A	donor_gain	0.9900
11:30442868:A:C	donor_gain	0.9900
11:30488565:A:AC	donor_gain	0.9900
11:30488566:C:CC	donor_gain	0.9900
11:30495294:AC:A	donor_gain	0.9900

AlphaMissense

1938 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:30417572:A:G	W200R	0.999
11:30417572:A:T	W200R	0.999
11:30417606:A:C	F188L	0.999
11:30417606:A:T	F188L	0.999
11:30417608:A:G	F188L	0.999
11:30536072:C:A	G78W	0.999
11:30536122:A:T	V61D	0.999
11:30580296:G:C	F26L	0.999
11:30580296:G:T	F26L	0.999
11:30580298:A:G	F26L	0.999
11:30411541:G:C	S271W	0.998
11:30414332:T:A	D221V	0.998
11:30414333:C:G	D221H	0.998
11:30495305:C:T	G176D	0.998
11:30495486:C:A	G116W	0.998
11:30495488:G:T	A115D	0.998
11:30536032:C:T	G91E	0.998
11:30536033:C:G	G91R	0.998
11:30536033:C:T	G91R	0.998
11:30536128:C:G	R59P	0.998
11:30411546:A:C	N269K	0.997
11:30411546:A:T	N269K	0.997
11:30414260:G:T	P245H	0.997
11:30414278:A:T	V239D	0.997
11:30414290:A:G	L235P	0.997
11:30414303:C:G	G231R	0.997
11:30414332:T:G	D221A	0.997
11:30417541:A:G	L210P	0.997
11:30417614:A:G	W186R	0.997
11:30417614:A:T	W186R	0.997

dbSNP variants (sampled 300 via entrez): RS1000036617 (11:30402018 C>T), RS1000064042 (11:30526016 T>C), RS1000078325 (11:30464022 A>G), RS1000093482 (11:30567734 C>T), RS1000094070 (11:30463645 C>G), RS1000098552 (11:30482764 T>C), RS1000107496 (11:30546778 G>A,C), RS1000120667 (11:30447660 C>A,T), RS1000129689 (11:30505977 A>G), RS1000168300 (11:30513107 T>C), RS1000172656 (11:30574335 T>A), RS1000178475 (11:30532317 G>A,T), RS1000181056 (11:30415932 T>C), RS1000194963 (11:30457015 G>A,T), RS1000229572 (11:30447235 C>A)

Disease associations

OMIM: gene MIM:600911 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

40 associations (top):

Study	Trait	p-value
GCST001244_1	Dental caries	8.000000e-06
GCST001466_1	Chronic kidney disease	8.000000e-18
GCST001606_1	Renal function-related traits (sCR)	3.000000e-09
GCST001607_2	Renal function-related traits (eGRFcrea)	1.000000e-09
GCST002358_14	Pit-and-Fissure caries	7.000000e-06
GCST003372_24	Glomerular filtration rate (creatinine)	6.000000e-18
GCST003374_8	Chronic kidney disease	9.000000e-08
GCST003401_37	Glomerular filtration rate in non diabetics (creatinine)	5.000000e-16
GCST003720_12	Migraine	4.000000e-08
GCST003790_23	Glomerular filtration rate	4.000000e-09
GCST003831_23	Asthma	9.000000e-07
GCST004292_27	Glomerular filtration rate (creatinine)	2.000000e-16
GCST005983_38	Serum uric acid levels	1.000000e-08
GCST005984_34	Glomerular filtration rate	8.000000e-22
GCST005985_52	Creatinine levels	3.000000e-21
GCST005986_38	Blood urea nitrogen levels	2.000000e-26
GCST006041_20	Major depressive disorder	8.000000e-08
GCST006291_22	Spherical equivalent or myopia (age of diagnosis)	4.000000e-08
GCST007267_120	Systolic blood pressure	1.000000e-10
GCST007324_78	Adventurousness	3.000000e-09
GCST007329_35	Automobile speeding propensity	1.000000e-14
GCST007344_19	Estimated glomerular filtration rate	9.000000e-36
GCST007344_65	Estimated glomerular filtration rate	5.000000e-07
GCST007565_37	Morning person	2.000000e-14
GCST007576_84	Chronotype	2.000000e-14
GCST007725_18	Serum uric acid levels	8.000000e-10
GCST007733_31	Serum uric acid levels	8.000000e-07
GCST007876_27	Estimated glomerular filtration rate	2.000000e-43
GCST007928_38	Medication use (diuretics)	4.000000e-08
GCST008971_43	Urate levels	6.000000e-08

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0004761	uric acid measurement
EFO:0004847	age at onset
EFO:0006335	systolic blood pressure
EFO:0008579	risk-taking behaviour
EFO:0008328	chronotype measurement
EFO:0009928	Diuretic use measurement
EFO:0004531	urate measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004615	apolipoprotein B measurement
EFO:0004530	triglyceride measurement
EFO:0004462	PR interval
EFO:0004980	appendicular lean mass
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, decreases expression, decreases methylation	5
Estradiol	decreases reaction, increases expression, affects cotreatment, decreases expression	4
methylmercuric chloride	decreases expression	3
sodium arsenite	affects methylation, decreases expression	2
entinostat	decreases expression, affects cotreatment	2
belinostat	decreases expression, affects cotreatment	2
Panobinostat	affects cotreatment, decreases expression	2
Benzo(a)pyrene	affects methylation, increases methylation	2
Nickel	decreases expression	2
Tretinoin	increases expression	2
aflatoxin B2	increases methylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	decreases expression	1
Air Pollutants	increases abundance, decreases expression	1
Coumestrol	increases expression, affects cotreatment	1
Doxorubicin	decreases expression	1
Rotenone	decreases expression	1
Tamoxifen	affects cotreatment, decreases expression	1
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression, increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	increases expression	1
Okadaic Acid	decreases expression	1
Raloxifene Hydrochloride	affects cotreatment, decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.